Pharma Foods International Co., Ltd.
TSE:2929.T
881 (JPY) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) JPY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 68,572 | 60,185 | 46,752 | 15,353.384 | 10,532.834 | 7,943.262 | 4,722.596 | 3,460.766 | 2,165.708 | 1,614.558 | 1,524.506 | 1,225.029 | 1,006.661 | 959.103 | 734.098 | 810.836 |
Cost of Revenue
| 13,293 | 12,077 | 7,027 | 3,178.214 | 1,996.281 | 1,591.887 | 1,006.208 | 1,001.862 | 787.352 | 712.185 | 630.919 | 658.309 | 589.249 | 515.864 | 488.904 | 534.76 |
Gross Profit
| 55,279 | 48,108 | 39,725 | 12,175.17 | 8,536.553 | 6,351.375 | 3,716.388 | 2,458.904 | 1,378.356 | 902.373 | 893.587 | 566.72 | 417.412 | 443.239 | 245.194 | 276.076 |
Gross Profit Ratio
| 0.806 | 0.799 | 0.85 | 0.793 | 0.81 | 0.8 | 0.787 | 0.711 | 0.636 | 0.559 | 0.586 | 0.463 | 0.415 | 0.462 | 0.334 | 0.34 |
Reseach & Development Expenses
| 840 | 766 | 522 | 437.684 | 317.162 | 274.243 | 241.976 | 313.243 | 243.57 | 199.753 | 172.004 | 172.699 | 133.955 | 164.384 | 174.597 | 224.154 |
General & Administrative Expenses
| 4,096 | 3,412 | 2,754 | 975.858 | 755.791 | 473.122 | 482.046 | 357.985 | 380.021 | 254.314 | 24.679 | 16.984 | 17.648 | 20.281 | 109.849 | 204.092 |
Selling & Marketing Expenses
| 38,865 | 35,748 | 24,860 | 7,376.019 | 4,926.01 | 3,637.975 | 1,774.804 | 1,188.656 | 790.066 | 223.126 | 82.69 | 64.945 | 58.461 | 61.717 | 0 | 0 |
SG&A
| 42,961 | 39,160 | 27,614 | 8,351.877 | 5,681.801 | 4,111.097 | 2,256.85 | 1,546.641 | 1,170.087 | 477.44 | 107.369 | 81.929 | 76.109 | 81.998 | 109.849 | 204.092 |
Other Expenses
| 89 | 7,100 | 5,913 | 2,645.587 | 1,961.335 | 41.056 | 42.388 | 78.88 | 39.655 | 21.717 | 19.05 | 45.287 | 61.054 | 64.162 | 53.833 | 53.433 |
Operating Expenses
| 51,667 | 47,026 | 34,049 | 11,435.148 | 7,960.298 | 6,054.943 | 2,518.452 | 1,859.886 | 1,561.511 | 802.172 | 472.794 | 408.69 | 377.701 | 431.63 | 423.822 | 602.81 |
Operating Income
| 3,610 | 1,080 | 5,673 | 740.018 | 576.253 | 296.428 | 89.436 | -46.35 | -371.854 | -28.131 | 217.058 | 70.775 | -44.279 | -63.947 | -264.169 | -452.314 |
Operating Income Ratio
| 0.053 | 0.018 | 0.121 | 0.048 | 0.055 | 0.037 | 0.019 | -0.013 | -0.172 | -0.017 | 0.142 | 0.058 | -0.044 | -0.067 | -0.36 | -0.558 |
Total Other Income Expenses Net
| -68 | 343 | 92 | 108.634 | 92.326 | 17.218 | -1,074.065 | -570.312 | -1.342 | -88.513 | -127.305 | -92.386 | -81.991 | 7.565 | -25.512 | -116.101 |
Income Before Tax
| 3,542 | 1,423 | 5,765 | 848.652 | 668.579 | 313.65 | 123.871 | 28.706 | -184.497 | 11.688 | 293.488 | 65.644 | -42.28 | 19.174 | -204.14 | -442.835 |
Income Before Tax Ratio
| 0.052 | 0.024 | 0.123 | 0.055 | 0.063 | 0.039 | 0.026 | 0.008 | -0.085 | 0.007 | 0.193 | 0.054 | -0.042 | 0.02 | -0.278 | -0.546 |
Income Tax Expense
| 462 | 1,797 | 1,924 | 157.705 | 160.766 | -8.864 | 18.582 | 2.41 | 3.389 | 2.856 | 24.141 | 5.61 | 4.321 | 3.927 | 3.435 | 12.181 |
Net Income
| 3,081 | -374 | 3,841 | 690 | 499.849 | 313.661 | 101.31 | 25.896 | -187.887 | 8.831 | 269.346 | 60.034 | -46.602 | 15.246 | -207.576 | -455.017 |
Net Income Ratio
| 0.045 | -0.006 | 0.082 | 0.045 | 0.047 | 0.039 | 0.021 | 0.007 | -0.087 | 0.005 | 0.177 | 0.049 | -0.046 | 0.016 | -0.283 | -0.561 |
EPS
| 106.7 | -12.89 | 132.21 | 23.79 | 17.21 | 10.8 | 3.49 | 0.89 | -6.49 | 0.34 | 11.46 | 2.56 | -1.98 | 0.65 | -8.83 | -19.36 |
EPS Diluted
| 106.7 | -12.89 | 132.14 | 23.78 | 17.21 | 10.8 | 3.49 | 0.89 | -6.49 | 0.34 | 11.45 | 2.55 | -1.98 | 0.65 | -8.83 | -19.36 |
EBITDA
| 4,198 | 1,811 | 5,959 | 949.279 | 730.742 | 453.757 | 1,333.913 | 720.463 | -76.112 | 165.773 | 540.387 | 236.168 | 149.311 | 135.016 | -64.465 | -222.09 |
EBITDA Ratio
| 0.061 | 0.03 | 0.127 | 0.062 | 0.069 | 0.057 | 0.282 | 0.208 | -0.035 | 0.103 | 0.354 | 0.193 | 0.148 | 0.141 | -0.088 | -0.274 |